First-generation antipsychotics, sometimes called “typical” antipsychotics, are a class of psychiatric drugs that work primarily by blocking dopamine receptors in the brain. Introduced in the 1950s with chlorpromazine, they were the first medications capable of reliably reducing hallucinations, delusions, and severe agitation. They remain widely prescribed today, though their side-effect profile, particularly the risk of involuntary movement disorders, has shaped decades of debate about when and how to use them.
How They Were Discovered
The story of first-generation antipsychotics begins, oddly enough, with synthetic dyes. The chemical backbone of phenothiazines, the molecular family that includes chlorpromazine, originated in the German dye industry in the late nineteenth century. By the early twentieth century, researchers had already repurposed phenothiazines as antiseptics and antimalarials. After World War II, French scientists exploring antihistamines synthesized chlorpromazine at Rhône-Poulenc Laboratories in the early 1950s. The goal was a better antihistamine; what they got instead was something that profoundly calmed agitated patients without simply sedating them into unconsciousness.1PubMed Central. History of the dopamine hypothesis of antipsychotic action
Chlorpromazine entered psychiatric use in Paris in 1952 and reached North America by 1954, though its adoption in the United States was slower, partly because psychoanalytic tradition dominated American psychiatry at the time.2PubMed. History of the discovery and clinical introduction of chlorpromazine Its effectiveness was dramatic: hospital wards that had been chaotic with severely psychotic patients became calmer, and discharge rates climbed. The commercial success of chlorpromazine spurred pharmaceutical companies to develop dozens of related compounds over the next two decades, creating the entire class now called first-generation antipsychotics.3PubMed Central. Fifty years chlorpromazine: a historical perspective
How First-Generation Antipsychotics Work
All first-generation antipsychotics share one core action: they block dopamine D2 receptors. Dopamine is a chemical messenger involved in many brain functions, from movement control to motivation to the sense that something in the environment is meaningful or important. In psychosis, the brain’s dopamine signaling in certain pathways appears to be overactive, causing stimuli and ideas to feel intensely significant when they are not. A neutral coincidence might feel like a cosmic message; a stranger’s glance might seem loaded with menace. Antipsychotics dampen that misplaced sense of significance, providing what researchers have described as a neurochemical platform for symptoms to resolve rather than directly erasing psychotic thoughts.4Progress in Neuro-Psychopharmacology and Biological Psychiatry. Half a century of antipsychotics and still a central role for dopamine D2 receptors
The problem is that dopamine D2 receptors are not just in the parts of the brain responsible for psychosis. They also sit in brain areas that coordinate movement and in pathways that regulate hormone release. Blocking receptors across all these regions at once is what gives first-generation antipsychotics their characteristic range of side effects, which we will get to shortly.
High-Potency Versus Low-Potency Types
First-generation antipsychotics are usually divided into two subgroups based on potency, which refers to how tightly the drug binds to dopamine receptors, not how “strong” it is in a colloquial sense. Low-potency drugs need higher milligram doses to achieve the same receptor blockade as high-potency drugs.5PubMed Central. Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia This distinction matters because the two subgroups tend to cause different patterns of side effects.
- High-potency examples: Haloperidol (Haldol), fluphenazine (Prolixin), and trifluoperazine. These bind D2 receptors very tightly at low doses. They are more likely to cause movement-related side effects but tend to produce less sedation and less drop in blood pressure.
- Low-potency examples: Chlorpromazine (Thorazine) and thioridazine. These require higher doses to achieve the same antipsychotic effect. They tend to be more sedating, more likely to lower blood pressure, and more likely to cause dry mouth and blurred vision, but they are somewhat less likely to trigger the stiffness and tremors associated with the high-potency drugs.
In practice, the choice between high-potency and low-potency versions often comes down to which side effects a particular patient can tolerate best. Someone who needs to stay alert during the day might do better on a high-potency drug at a low dose, while someone with severe agitation or insomnia might benefit from the sedating qualities of a low-potency drug.
What They Are Used For
The primary use of first-generation antipsychotics is treating psychotic disorders, above all schizophrenia. They are effective at reducing what clinicians call “positive symptoms,” the features of psychosis that represent something added to a person’s experience, like hearing voices, seeing things that are not there, or holding fixed false beliefs. In first-episode psychosis, evidence suggests that first-generation and second-generation antipsychotics are similarly effective at controlling these core symptoms, though the newer drugs tend to be better tolerated.6PubMed Central. Treatment Principles of First-Episode Psychosis
Beyond schizophrenia, haloperidol is commonly used in emergency settings for acute agitation regardless of cause. It has a long track record for managing severe mania in bipolar disorder. Chlorpromazine and haloperidol are also used for intractable hiccups, a use that might sound trivial until you consider that hiccups lasting days or weeks can be debilitating. Studies have reported complete resolution of persistent hiccups with chlorpromazine at doses of 10 to 25 mg and haloperidol at 1 to 2 mg.7PubMed Central. A Systematic Comparative Review of Antipsychotic Efficacy and Safety in the Treatment of Hiccups Chlorpromazine is also used for nausea and vomiting that does not respond to first-line treatments, and haloperidol sees use in palliative care for delirium in terminally ill patients.
Movement-Related Side Effects
The side effects that most define this drug class are the extrapyramidal symptoms, a term that covers several types of abnormal movement. They happen because blocking D2 receptors in the brain’s movement-control areas disrupts the fine-tuned coordination between structures that normally keep your muscles working smoothly.8PubMed Central. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies
These movement problems come in several flavors, and the timing matters:
- Acute dystonia: Sudden, painful muscle contractions, often in the neck, jaw, or eyes, that can begin within hours or days of starting treatment. These are frightening but treatable with injectable medications.
- Parkinsonism: Tremor, stiffness, shuffling gait, and a mask-like facial expression that resemble Parkinson’s disease. This typically appears within the first few weeks.
- Akathisia: An intensely distressing inner restlessness that makes a person feel unable to sit still. It can appear within days and is one of the most common reasons people stop taking their medication.
- Tardive dyskinesia: Involuntary, repetitive movements, often of the face, tongue, and jaw, such as lip smacking or tongue protrusion. Unlike the others, this tends to emerge after months or years of treatment and can be irreversible.
Tardive dyskinesia is the most feared of these because it can persist even after the drug is stopped. A systematic review of one-year studies found that the annual incidence of tardive dyskinesia in adults treated with haloperidol was about 5.4%, compared to roughly 0.8% in adults treated with second-generation antipsychotics.9PubMed. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies The underlying mechanism involves prolonged dopamine receptor blockade leading to a kind of oversensitivity in the movement-control circuits.10PubMed. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction The risk rises with age, higher doses, and longer treatment duration.
Hormonal and Metabolic Effects
Because dopamine normally keeps the pituitary gland’s release of prolactin in check, blocking D2 receptors there causes prolactin levels to rise. This is called hyperprolactinemia, and it can produce symptoms in both men and women: breast tenderness, breast enlargement, milk production unrelated to pregnancy, irregular or absent menstrual periods, and reduced sex drive. Over the long term, the resulting suppression of estrogen and testosterone can affect bone density.11Prescriber Update. Hyperprolactinaemia With Antipsychotics
Prolactin elevation was once thought of as a problem specific to first-generation drugs, but some second-generation antipsychotics, such as risperidone and paliperidone, raise prolactin just as much or more.12The Lancet. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis This is one of the clearest illustrations that the line between “typical” and “atypical” antipsychotics is blurrier than the two-generation labeling suggests.
Heart Rhythm Concerns
Some first-generation antipsychotics can lengthen a specific interval in the heart’s electrical cycle, known as the QTc interval. When this interval stretches too far, it increases the risk of a dangerous irregular heartbeat. Research has confirmed that first-generation antipsychotics do affect QTc, and that age, sex, alcohol misuse, and concurrent medications that also affect heart rhythm can compound the risk.13PubMed. First-generation antipsychotics and QTc: any role for mediating variables? Adding a first-generation antipsychotic on top of another antipsychotic has been shown to increase QTc more than switching from one to the other, which is one practical reason why combining antipsychotics requires careful monitoring.14PubMed. The use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval
Thioridazine and droperidol carry the highest QTc risk among first-generation drugs. In practice, this means prescribers often order a baseline electrocardiogram before starting treatment and monitor periodically, especially when the patient is older or takes other medications that affect the heart.
Neuroleptic Malignant Syndrome
The rarest but most dangerous side effect is neuroleptic malignant syndrome, a medical emergency characterized by very high fever, severe muscle rigidity, confusion, and instability in heart rate and blood pressure. It can occur with any antipsychotic, though it has historically been most associated with high-potency first-generation drugs at higher doses. The condition is unpredictable and can develop at any point in treatment. There is no reliable way to predict who will be affected, and despite decades of case reports, robust evidence-based treatment guidelines remain limited. Emergency care usually involves stopping the antipsychotic immediately, providing intensive supportive care, and sometimes using muscle relaxants or dopamine-boosting drugs.15PubMed Central. An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome
How Patients Actually Feel on These Drugs
Side-effect lists in a medical textbook tend to sound clinical and abstract, but the lived experience of taking first-generation antipsychotics has a character that matters for understanding why so many people stop taking them. A cross-sectional study of outpatients with schizophrenia on first-generation antipsychotics found that over half reported feeling tired and sluggish, and nearly half described a “zombie-like” sensation.16PubMed Central. Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study The high-potency drugs in particular have been linked to a phenomenon called antipsychotic-induced dysphoria, a distinct unpleasant emotional flatness or inner misery that goes beyond ordinary sedation.17PubMed. Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence
This matters enormously for adherence. A medication that controls hallucinations but makes you feel like a hollow version of yourself creates a painful dilemma. Many people who stop their antipsychotic do so not because the drug failed to work on their symptoms but because the subjective experience of taking it felt unbearable. Recognizing dysphoria and distinguishing it from depression or the negative symptoms of schizophrenia itself is something that clinicians can miss if they are focused only on whether the voices have stopped.
Managing Side Effects When They Occur
For akathisia, the evidence supports several approaches: reducing the antipsychotic dose if the psychosis is sufficiently controlled, switching to a different antipsychotic, or adding a beta-blocker (propranolol is the most studied). Benzodiazepines, certain serotonin-blocking agents, and high-dose vitamin B6 have also shown benefit.18PubMed Central. The Assessment and Treatment of Antipsychotic-Induced Akathisia Anticholinergic drugs like benztropine or trihexyphenidyl are the standard treatment for acute dystonia and parkinsonism, though they come with their own side effects, including dry mouth, constipation, and memory difficulties.
For tardive dyskinesia, stopping the antipsychotic can sometimes help, but the movements may persist or even temporarily worsen after discontinuation. In recent years, two drugs that work by depleting dopamine at nerve terminals, valbenazine and deutetrabenazine, have become available specifically for tardive dyskinesia. Prevention remains the best strategy: using the lowest effective dose, monitoring regularly for early signs of abnormal movements, and considering a switch to a lower-risk antipsychotic when feasible.
First-Generation Versus Second-Generation Antipsychotics
The arrival of second-generation (atypical) antipsychotics in the 1990s was initially hailed as a revolution, with claims that the newer drugs were both more effective and much safer. Decades of comparative research have painted a more nuanced picture. A large systematic review and meta-analysis found few differences of clinical importance in core symptom control between the two generations, and stated that clear benefits of first-generation over second-generation drugs, or vice versa, remain inconclusive for most comparisons.19PubMed. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis
Where the generations do differ more consistently is in their side-effect profiles. Meta-analyses of first-episode psychosis trials found that second-generation drugs produced fewer extrapyramidal symptoms and less akathisia, but caused more weight gain.20International Journal of Neuropsychopharmacology. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis A network meta-analysis of 32 oral antipsychotics confirmed this general pattern: older drugs produced more movement side effects and prolactin elevation, while newer drugs tended toward more weight gain and sedation, though there were notable exceptions in both directions.12The Lancet. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
The takeaway is that “first-generation” and “second-generation” are marketing-era labels more than they are clean pharmacological categories. Adverse-effect profiles are specific to each individual antipsychotic and do not neatly fit the generational classification.21PubMed Central. Management of common adverse effects of antipsychotic medications. Risperidone raises prolactin like a first-generation drug; chlorpromazine causes weight gain like a second-generation drug. Picking the right antipsychotic is about matching the specific drug’s profile to the specific patient’s risks and priorities, not about choosing a generation.
Older Adults and Dementia
First-generation antipsychotics are sometimes prescribed to older adults with dementia who experience agitation, aggression, or psychotic symptoms. This is one of the most fraught areas in their use. Antipsychotics in dementia patients have been linked to increased mortality and a range of adverse events including pneumonia, stroke, worsened parkinsonism, and blood clots.22PubMed Central. Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update
The data on whether first-generation drugs are riskier than second-generation ones in this population is complicated. A meta-analysis pooling data from over 380,000 dementia patients found that antipsychotic use generally was associated with greater mortality.23PubMed Central. Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care A separate meta-analysis focused specifically on conventional (first-generation) antipsychotics in randomized placebo-controlled trials found a pooled risk difference that was not statistically significant, though the total number of deaths was small and the trials were short.24Journal of the American Medical Directors Association. The Mortality Risk of Conventional Antipsychotics in Elderly Patients: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials The upshot is that both generations carry risk in elderly dementia patients, and antipsychotics should be used sparingly, at the lowest possible dose, for the shortest possible time, and only after non-drug approaches have been tried.
Genetics and Why Side Effects Hit Some People Harder
One persistent puzzle is why two patients on the same drug at the same dose can have completely different experiences, one tolerating it well and the other developing severe tardive dyskinesia within months. Part of the answer is genetic. The enzyme CYP2D6, which metabolizes many first-generation antipsychotics, varies considerably from person to person. A study found that people who carry just one mutated copy of the gene for this enzyme had a significantly higher incidence of tardive dyskinesia compared to people without such mutations, with rates of about 81% versus 46%.25Schizophrenia Research. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia Even subtle differences in how quickly your body breaks down the drug can mean the difference between a safe blood level and one that keeps your dopamine receptors blocked harder and longer than intended.
Pharmacogenomic testing, which checks your genetic profile to predict how you metabolize certain drugs, is available and increasingly used in psychiatry, though it is far from universal. For someone starting a first-generation antipsychotic, knowing whether they are a slow metabolizer of CYP2D6 substrates could inform the starting dose and the level of monitoring. The science here is still evolving, but it represents one of the most promising avenues for making these older drugs safer for individual patients.
Why First-Generation Antipsychotics Still Matter
Given the side-effect burden, you might wonder why anyone would still prescribe these drugs. Several reasons keep them in active use. Cost is one: many first-generation antipsychotics are available as cheap generics, which makes them essential in health systems with limited budgets. Haloperidol decanoate, a long-acting injectable form, is one of the most affordable options for patients who have difficulty taking daily pills. In emergency medicine, injectable haloperidol remains a workhorse for managing acute agitation because of its rapid onset and decades of clinical experience. And for certain patients, a first-generation drug simply works better or is tolerated better than anything else they have tried. Psychiatric treatment is deeply individual, and the “best” antipsychotic is whichever one a given patient can take reliably with acceptable side effects and adequate symptom control.